# Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

> **NCT03846583** · PHASE1 · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tucatinib
- **DRUG:** Abemaciclib
- **DRUG:** Trastuzumab
- **DRUG:** Aromatase Inhibitor

## Key facts

- **NCT ID:** NCT03846583
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-28
- **Primary completion:** 2020-09-22
- **Final completion:** 2020-09-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study halted prematurely, prior to enrollment of first participant.
- **Last updated:** 2020-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03846583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03846583, "Tucatinib + Abemaciclib + Herceptin for HER2+ MBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03846583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*